8-K: Intelligent Bio Solutions Achieves 94.1% Accuracy in Drug Screening System Study, Eyes FDA Submission

Intelligent Bio Solutions has successfully completed a method comparison study for its fingerprint drug screening system, demonstrating 94.1% accuracy and paving the way for an FDA 510(k) submission.

Summary

• Intelligent Bio Solutions Inc. has announced the successful completion of a method comparison study for its Intelligent Fingerprinting Drug Screening System.
• The study, conducted with 135 healthy donors and nine system operators, showed the system achieved 82.2% sensitivity, 100% specificity, and 94.1% accuracy.
• The method comparison study compared the fingerprint sweat opiate screening tests with results from a validated liquid chromatography-mass spectrometry method.
• The company expects to submit its FDA 510(k) application in the fourth calendar quarter of 2024, including data from both the method comparison and a recent pharmacokinetic study.
• The company believes that FDA clearance would allow them to introduce their technology to the US market in 2025.

Sentiment

Score: 8

Explanation: The document presents very positive results from a key study, indicating a significant step towards commercialization and regulatory approval. The high accuracy and ease of use of the system are strong positives, leading to a high sentiment score.

Positives

• The method comparison study validates the accuracy and reliability of the fingerprint-based drug screening system.
• The system's high specificity of 100% indicates a low rate of false positives.
• The system is easy to use, with no usage errors reported during the study.
• The company is on track to submit its FDA 510(k) application in the fourth quarter of 2024.
• The technology has potential for use in various sectors, including workplace drug testing, law enforcement, and drug rehabilitation.

Risks

• The company's ability to successfully develop and commercialize its drug and diagnostic tests is subject to risks and uncertainties.
• The company's ability to secure regulatory approvals is not guaranteed.
• The company's expectations may prove to be materially different from the results expressed or implied by forward-looking statements.

Future Outlook

The company anticipates submitting its FDA 510(k) application in the fourth calendar quarter of 2024 and expects to introduce its technology to the US market in 2025, pending FDA clearance.

Management Comments

• Harry Simeonidis, President and CEO, stated that the study reaffirms the accuracy and reliability of their fingerprint-based drug screening system.
• Harry Simeonidis also mentioned that the accomplishment is a significant step toward transforming drug testing with non-invasive technology.

Industry Context

This announcement is relevant to the broader trend of non-invasive and rapid testing solutions in the medical technology industry, particularly in drug screening. The company is positioning itself to compete in the workplace drug testing market, which is a growing sector.

Comparison to Industry Standards

• The 94.1% accuracy achieved by Intelligent Bio Solutions' system is a strong result when compared to traditional drug testing methods, such as urine or blood tests, which can have varying levels of accuracy and are more invasive.
• The use of fingerprint sweat analysis is a novel approach, and the company's results are competitive with other emerging non-invasive testing technologies.
• While specific competitor data is not provided in the document, the company's focus on speed, accuracy, and non-invasiveness positions it well against established players in the drug testing market.

Stakeholder Impact

• Shareholders will likely view the positive study results as a positive step towards commercialization and revenue generation.
• Potential customers in safety-critical industries will be interested in the system's accuracy and non-invasive nature.
• Employees may benefit from a safer work environment due to more effective drug screening.

Next Steps

• The company will submit its FDA 510(k) application in the fourth calendar quarter of 2024.
• The company plans to introduce its technology to the US market in 2025, pending FDA clearance.

Key Dates

Keywords

drug screening, fingerprint analysis, FDA 510(k), method comparison study, pharmacokinetic study, medical technology, non-invasive testing, workplace drug testing, opiate screening, accuracy, sensitivity, specificity